百利天恒:近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新药镥[177Lu]-BL-ARC001注射液(BL-ARC001)的药物临床试验获得批准。BL-ARC001是公司在抗体放射性核素偶联物(ARC)领域的首款I类创新药物,也是公司拥有完全自主知识产权的潜在全球首创(First-in-class)的ARC药物。多瑞医药:公司股票自2025年9月...
Source Link百利天恒:近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新药镥[177Lu]-BL-ARC001注射液(BL-ARC001)的药物临床试验获得批准。BL-ARC001是公司在抗体放射性核素偶联物(ARC)领域的首款I类创新药物,也是公司拥有完全自主知识产权的潜在全球首创(First-in-class)的ARC药物。多瑞医药:公司股票自2025年9月...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.